Apimeds Pharmaceuticals Us Stock Market Value
| APUS Stock | 1.78 0.07 3.78% |
| Symbol | Apimeds |
Is there potential for Diversified Capital Markets market expansion? Will Apimeds introduce new products? Factors like these will boost the valuation of Apimeds Pharmaceuticals. If investors know Apimeds will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apimeds Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Apimeds Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Apimeds's balance sheet. Smart investors calculate Apimeds Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Apimeds Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Apimeds Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apimeds Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Apimeds Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Apimeds Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apimeds Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apimeds Pharmaceuticals.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Apimeds Pharmaceuticals on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Apimeds Pharmaceuticals US or generate 0.0% return on investment in Apimeds Pharmaceuticals over 90 days. Apimeds Pharmaceuticals is related to or competes with Talphera, MIRA Pharmaceuticals, Scynexis, Milestone Scientific, India Globalization, Precision Optics, and Q32 Bio. Apimeds Pharmaceuticals is entity of United States More
Apimeds Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apimeds Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apimeds Pharmaceuticals US upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.33 | |||
| Information Ratio | 0.0238 | |||
| Maximum Drawdown | 59.03 | |||
| Value At Risk | (20.79) | |||
| Potential Upside | 15.05 |
Apimeds Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apimeds Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apimeds Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Apimeds Pharmaceuticals historical prices to predict the future Apimeds Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0308 | |||
| Jensen Alpha | 0.2204 | |||
| Total Risk Alpha | (0.34) | |||
| Sortino Ratio | 0.0257 | |||
| Treynor Ratio | 0.201 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Apimeds Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Apimeds Pharmaceuticals February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0308 | |||
| Market Risk Adjusted Performance | 0.211 | |||
| Mean Deviation | 7.04 | |||
| Semi Deviation | 8.81 | |||
| Downside Deviation | 9.33 | |||
| Coefficient Of Variation | 3409.69 | |||
| Standard Deviation | 10.07 | |||
| Variance | 101.43 | |||
| Information Ratio | 0.0238 | |||
| Jensen Alpha | 0.2204 | |||
| Total Risk Alpha | (0.34) | |||
| Sortino Ratio | 0.0257 | |||
| Treynor Ratio | 0.201 | |||
| Maximum Drawdown | 59.03 | |||
| Value At Risk | (20.79) | |||
| Potential Upside | 15.05 | |||
| Downside Variance | 87.0 | |||
| Semi Variance | 77.54 | |||
| Expected Short fall | (8.90) | |||
| Skewness | 0.1813 | |||
| Kurtosis | 1.61 |
Apimeds Pharmaceuticals Backtested Returns
Apimeds Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0188, which signifies that the company had a -0.0188 % return per unit of risk over the last 3 months. Apimeds Pharmaceuticals US exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Apimeds Pharmaceuticals' Downside Deviation of 9.33, mean deviation of 7.04, and Risk Adjusted Performance of 0.0308 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.42, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Apimeds Pharmaceuticals will likely underperform. At this point, Apimeds Pharmaceuticals has a negative expected return of -0.19%. Please make sure to confirm Apimeds Pharmaceuticals' sortino ratio, as well as the relationship between the semi variance and rate of daily change , to decide if Apimeds Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.19 |
Insignificant reverse predictability
Apimeds Pharmaceuticals US has insignificant reverse predictability. Overlapping area represents the amount of predictability between Apimeds Pharmaceuticals time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apimeds Pharmaceuticals price movement. The serial correlation of -0.19 indicates that over 19.0% of current Apimeds Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.19 | |
| Spearman Rank Test | -0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.